Session

Scientific basis of experimental therapy in bladder cancer

Poster Session 73

  • Location:
    Room Vienna (Hall B2, level 0)
  • Chairs:
     N. Fujimoto, Kitakyushu (JP)
     M. Knowles, Leeds (GB)
     M. Sanchez-Carbayo, Vitoria-Gasteiz (ES)
  • Aims and objectives of this session

    Transcription factors have been investigated in multiple tumours in order to improve chemotherapy. Targeting these transcription factors in urothelial cancer will be presented. In addition, the session will address the role of modulation of tumour metabolism and inhibition of steroid receptors in that tumour.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
924
Prediction of therapeutic resistance using ERBB2 expression status and Ki-67 labelling index in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach

By: Inoue M.1, Koga F.2, Yoshida S.1, Tanaka H.1, Kobayashi S.1, Yokoyama M.1, Ishioka J.1, Matsuoka Y.1, Numao N.1, Saito K.1, Fujii Y.1, Kihara K.1

Institutes: 1Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan, 2Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Dept. of Urology, Tokyo, Japan

* 925
STAT1 inhibition restored chemotherapy sensitivity in cisplatin/gemcitabine resistant bladder cancer

By: Hayashi T.1, Seiler R.2, Bell R.2, Ettinger S.2, Wang K.2, Goriki A.2, Oo H.Z.2, Awrey S.2, Gust K.2, Jaeger W.2, Todenhöfer T.2, Altamirano-Dimas M.2, Matsubara A.1, Collins C.2, Black P.2

Institutes: 1Hiroshima University, Dept. of Urology, Hiroshima, Japan, 2Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada

926
Transcription factor STAT3 is a potential therapeutic target in bladder cancer

By: Schmid S.C., Yousef A., Sathe A., Horn T., Maurer T., Retz M., Gschwend J.E., Holm P.S., Nawroth R.

Institutes: Technische Universität München, Dept. of Urology, Munich, Germany

927
Effective treatment of cisplatin-resistant bladder cancer using a glycosaminoglycan binding malaria protein

By: Seiler R.1, Oo H.1, Lee S.1, Tortora D.1, Kumar G.1, Chris W.1, Clausen T.M.2, Agerbæk M.Ø.2, Gustavsson T.2, Rich J.R.3, Babcook J.3, Black P.C.4, Salanti A.2, Daugaard M.1

Institutes: 1University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, 2Centre For Medical Parasitology, Dept. of Immunology and Microbiology, University of Copenhagen and Department of Infectious Diseases, Copenhagen, Denmark, 3Centre For Drug Research and Development, Dept. of Pharmaceutical Sciences, Vancouver, Canada, 4University of British Columbia, Dept of Urologic Sciences, Vancouver, Canada

928
Androgen receptor signals reduce sensitivity to cisplatin in bladder cancer cells

By: Kashiwagi E.1, Ide H.2, Kawahara T.2, Reis L.2, Eto M.1, Miyamoto H.2, Baras A.2

Institutes: 1Kyushu University, Dept. of Urology, Fukuoka, Japan, 2Johns Hopkins School of Medicine, Dept. of Pathology, Baltimore, United States of America

* 929
Targeting lactate transporters for the treatment of urothelial carcinoma

By: Todenhöfer T.1, Seiler R.1, Stewart C.1, Moskalev I.1, Gao J.1, Ladar S.1, Kamyabi A.1, Al Nakouzi N.1, Hayashi T.1, Choi S.1, Wang Y.1, Frees S.1, Daugaard M.1, Zarni Ooh H.1, Hennenlotter J.2, Bedke J.2, Fazli L.1, Stenzl A.2, Black P.1

Institutes: 1University of British Columbia, Vancouver Prostate Centre, Vancouver, Canada, 2Eberhard-Karls-Universität, Dept. of Urology, Tübingen, Germany

930
The PCNA targeting peptide drug ATX-101 enhances the efficacy of intravenous chemotherapy for muscle-invasive bladder cancer in a orthotopic rat bladder model

By: Blindheim A.J.1, Søgaard C.D.2, Gederaas O.2, Viset T.3, Arum C-J.1, Otterlei M.2

Institutes: 1St. Olavs Hospital, University Hospital of Trondheim, Dept. of Surgery, Trondheim, Norway, 2The Norwegian University of Science and Technology, Dept. of Cancer Research and Molecular Medicine, Trondheim, Norway, 3St. Olavs Hospital, University Hospital of Trondheim, Dept. of Pathology, Trondheim, Norway

931
Synergistic antitumor effect of satraplatin and NVP-BEZ235 in cisplatin-resistant human bladder cancer cells

By: Yoon C.Y.1, Kong M.K.1, Ahn H.G.1, Kang S.G.1, Han J.H.1, Kang Y.J.1, Jang W.S.1, Lee J.S.2, Kim Y.S.3, Park H.S.4, Cho I.R.5, Cheon J.4, Choi Y.D.1

Institutes: 1Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, 2Cheil General Hospital and Women’s Healthcare Center, Dankook University, College of Medicine, Dept. of Urology, Seoul, South Korea, 3National Health Insurance Service Ilsan Hospital, Dept. of Urology, Ilsan, South Korea, 4Korea University, College of Medicine, Dept. of Urology, Seoul, South Korea, 5Inje University, Ilsan Paik Hospital, Dept. of Urology, Ilsan, South Korea

932
HYAL4: A novel molecular biomarker and determinant of bladder cancer

By: Hennig M.1, Lokeshwar S.2, Knapp J.3, Hupe M.1, Kramer M.1, Manoharan M.2, Merseburger A.1, Lokeshwar V.4

Institutes: 1University Of Lübeck, Dept. of Urology, Lübeck, Germany, 2Miller-School of Medicine, Dept. of Urology, Miami, United States of America, 3University of Lübeck, Dept. of Urology, Lübeck, Germany, 4Medical College of Georgia, Dept. of Biochemistry & Molecular Biology, Augusta, United States of America

933
Establishment of a new orthotopic in vivo examinable model of non-muscle invasive bladder cancer using RT112 reporter cells

By: Fragoulis A.1, Fera C.2, Schemmert S.2, Strick K.2, Anton M.3, Möhring M.4, Steitz J.4, Tolba R.4, Grosse J.O.2

Institutes: 1Uniklinik RWTH Aachen, Dept. of Orthopaedic Surgery, Aachen, Germany, 2Uniklinik RWTH Aachen, Dept. of Urology, Aachen, Germany, 3TU Munich, Institute of Molecular Immunology and Experimental Oncology, Munich, Germany, 4Uniklinik RWTH Aachen, Institute for Laboratory Animal Science, Aachen, Germany

934
Tumour-suppressive microRNA-26a/b inhibit cancer cell migration and invasion through targeting collagen cross-linking enzyme, PLOD2 in bladder cancer

By: Miyamoto K.1, Seki N.2, Matsushita R.1, Yonemori M.1, Yoshino H.1, Goto Y.2, Kato M.2, Kurozumi A.2, Nakagawa M.1, Enokida H.1

Institutes: 1Kagoshima University Graduate School of Medical and Dental Sciences, Dept. of Urology, Kagoshima, Japan, 2Chiba University Graduate School of Medicine, Dept. of Functional Genomics, Chiba, Japan

935
Potential role of an IRE1α/XBP1 inhibitor in preventing therapeutic failure of intravesical BCG in bladder cancer

By: Lewicki P.1, Liu H.1, Golombos D.1, O’Malley P.1, Cubillos-Ruiz J.2, Scherr D.1

Institutes: 1Weill Cornell Medical College, Dept. of Urology, New York, United States of America, 2Weill Cornell Medical College, Dept. of Obstetrics and Gynaecology, New York, United States of America

937
Attenuated XPC expression is not associated with impaired DNA repair in bladder cancer

By: Boormans J.L.1, Naipal K.A.T.2, Raams A.2, Van Leenders G.J.L.H.3, Kanaar R.4, Van Gent D.C.2

Institutes: 1Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, 2Erasmus MC, Dept. of Genetics, Rotterdam, The Netherlands, 3Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, 4Erasmus MC, Dept. of Radiation Oncology, Rotterdam, The Netherlands